Literature DB >> 27518620

Using β-Lactamase and NanoLuc Luciferase Reporter Gene Assays to Identify Inhibitors of the HIF-1 Signaling Pathway.

Thai Khuc1, Chia-Wen Amy Hsu1, Srilatha Sakamuru1, Menghang Xia2.   

Abstract

The hypoxia-inducible factor 1 (HIF-1) is a transcriptional factor involved in the regulation of oxygen within cellular environments. In hypoxic tissues or those with inadequate oxygen concentrations, activation of the HIF-1 transcription factor allows for subsequent activation of target gene expression implicated in cell survival. As a result, cells proliferate through formation of new blood vessels and expansion of vascular systems, providing necessary nourishment needed of cells. HIF-1 is also involved in the complex pathophysiology associated with cancer cells. Solid tumors are able to thrive in hypoxic environments by overactivating these target genes in order to grow and metastasize. Therefore, it is of high importance to identify modulators of the HIF-1 signaling pathway for possible development of anticancer drugs and to better understand how environmental chemicals cause cancer. Using a quantitative high-throughput screening (qHTS) approach, we are able to screen large chemical libraries to profile potential small molecule modulators of the HIF-1 signaling pathway in a 1536-well format. This chapter describes two orthogonal cell based assays; one utilizing a β-lactamase reporter gene incorporated into human ME-180 cervical cancer cells, and the other using a NanoLuc luciferase reporter system in human HCT116 colon cancer cells. Cell viability assays for each cell line are also conducted respectively. The data from this screening platform can be used as a gateway to study mode of action (MOA) of selected compounds and drug classes.

Entities:  

Keywords:  Beta-lactamase; Cancer; Drug; FRET; Fluorescence resonance energy transfer; Genome editing; Hypoxia inducible factor 1; Hypoxia response elements; Luciferase; NanoLuc; Quantitative high-throughput screening; Reporter gene; qHTS

Mesh:

Substances:

Year:  2016        PMID: 27518620      PMCID: PMC5375166          DOI: 10.1007/978-1-4939-6346-1_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  11 in total

1.  Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes.

Authors:  S Salceda; J Caro
Journal:  J Biol Chem       Date:  1997-09-05       Impact factor: 5.157

2.  Synthesis and evaluation of quinazolin-4-ones as hypoxia-inducible factor-1α inhibitors.

Authors:  Wenwei Huang; Ruili Huang; Matias S Attene-Ramos; Srilatha Sakamuru; Erika E Englund; James Inglese; Christopher P Austin; Menghang Xia
Journal:  Bioorg Med Chem Lett       Date:  2011-07-21       Impact factor: 2.823

3.  Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch.

Authors:  David Lando; Daniel J Peet; Dean A Whelan; Jeffrey J Gorman; Murray L Whitelaw
Journal:  Science       Date:  2002-02-01       Impact factor: 47.728

4.  Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension.

Authors:  B H Jiang; G L Semenza; C Bauer; H H Marti
Journal:  Am J Physiol       Date:  1996-10

Review 5.  Recent agents targeting HIF-1α for cancer therapy.

Authors:  Yaozhong Hu; Jing Liu; He Huang
Journal:  J Cell Biochem       Date:  2013-03       Impact factor: 4.429

6.  Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway.

Authors:  L E Huang; J Gu; M Schau; H F Bunn
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

7.  Purification and characterization of hypoxia-inducible factor 1.

Authors:  G L Wang; G L Semenza
Journal:  J Biol Chem       Date:  1995-01-20       Impact factor: 5.157

8.  Identification of chemical compounds that induce HIF-1alpha activity.

Authors:  Menghang Xia; Ruili Huang; Yi Sun; Gregg L Semenza; Shelley Force Aldred; Kristine L Witt; James Inglese; Raymond R Tice; Christopher P Austin
Journal:  Toxicol Sci       Date:  2009-06-05       Impact factor: 4.849

9.  Identification of small molecule compounds that inhibit the HIF-1 signaling pathway.

Authors:  Menghang Xia; Kun Bi; Ruili Huang; Ming-Hsuang Cho; Srilatha Sakamuru; Susanne C Miller; Hua Li; Yi Sun; John Printen; Christopher P Austin; James Inglese
Journal:  Mol Cancer       Date:  2009-12-09       Impact factor: 27.401

10.  Identification of approved and investigational drugs that inhibit hypoxia-inducible factor-1 signaling.

Authors:  Chia-Wen Hsu; Ruili Huang; Thai Khuc; David Shou; Joshua Bullock; Suzanne Grooby; Sue Griffin; Chaozhong Zou; Annette Little; Holly Astley; Menghang Xia
Journal:  Oncotarget       Date:  2016-02-16
View more
  2 in total

1.  Curcumin and NCLX inhibitors share anti-tumoral mechanisms in microsatellite-instability-driven colorectal cancer.

Authors:  William Raoul; Thierry Lecomte; Maxime Guéguinou; Sajida Ibrahim; Jérôme Bourgeais; Alison Robert; Trayambak Pathak; Xuexin Zhang; David Crottès; Jacques Dupuy; David Ternant; Valérie Monbet; Roseline Guibon; Hector Flores-Romero; Antoine Lefèvre; Stéphanie Lerondel; Alain Le Pape; Jean-François Dumas; Philippe G Frank; Alban Girault; Romain Chautard; Françoise Guéraud; Ana J García-Sáez; Mehdi Ouaissi; Patrick Emond; Olivier Sire; Olivier Hérault; Gaëlle Fromont-Hankard; Christophe Vandier; David Tougeron; Mohamed Trebak
Journal:  Cell Mol Life Sci       Date:  2022-05-08       Impact factor: 9.261

2.  BaroFuse, a novel pressure-driven, adjustable-throughput perfusion system for tissue maintenance and assessment.

Authors:  Austin Rountree; Amit Karkamkar; Gamal Khalil; Albert Folch; Daniel L Cook; Ian R Sweet
Journal:  Heliyon       Date:  2016-12-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.